Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Supernus Pharmaceuticals, Inc.

NASDAQ: SUPN · Life Sciences · 7 alerts · CIK 1356576

Share price
$28.83Close, Nov 16
Market cap
$1.68B
Shares outstanding
58.24MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Supernus Pharmaceuticals, Inc. filings on SEC EDGAR ↗

6:03 AM ET 8-K
Regulatory Approval

Supernus Pharmaceuticals Regulatory Approval

The FDA has recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in advanced Parkinson’s disease. The exclusivity period is retroactive to the drug's approval date of February 3, 2025, and the company has also submitted an sNDA for a second supplier to ensure long-term supply stability.

Term
7 years

“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”

Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.